Erectile dysfunction : a global review of intracavernosal injectables

PURPOSE: Data assessing the effectiveness of intracavernosal injections (ICIs) for the treatment of erectile dysfunction (ED) are limited. This study evaluates intracavernosal injectable therapies for ED and reviews available guidelines that inform clinical practice

Bibliographic Details
Published in:World journal of urology, Vol. 37, No. 6 (2019), p. 1007-1014
Main Author: Duncan, Catriona
Other Involved Persons: Omran, Ghadir J ; Teh, Jiasian ; Davis, Niall F ; Bolton, Damien M ; Lawrentschuk, Nathan
Format: electronic Article
Language:English
ISSN:1433-8726
Item Description:Date Revised 10.06.2019
published: Print-Electronic
Citation Status In-Process
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Physical Description:Online-Ressource
DOI:10.1007/s00345-019-02727-5
Subjects:
QR Code: Show QR Code
LEADER 03459nma a2200541 c 4500
001 NLM295727896
003 DE-601
005 20190611042907.0
007 cr uuu---uuuuu
008 190326s2019 000 0 eng d
024 7 |a 10.1007/s00345-019-02727-5  |2 doi 
028 5 2 |a pubmed19n1225.xml 
035 |a (DE-599)NLM30895359 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Duncan, Catriona 
245 1 0 |a Erectile dysfunction  |h Elektronische Ressource  |b a global review of intracavernosal injectables 
300 |a Online-Ressource 
500 |a Date Revised 10.06.2019 
500 |a published: Print-Electronic 
500 |a Citation Status In-Process 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a PURPOSE: Data assessing the effectiveness of intracavernosal injections (ICIs) for the treatment of erectile dysfunction (ED) are limited. This study evaluates intracavernosal injectable therapies for ED and reviews available guidelines that inform clinical practice 
520 |a METHODS: A systematic search using electronic databases (Medline, Pubmed) was performed for studies investigating injectable management strategies for ED published after 1990. Primary outcome measures were to comparatively evaluate clinical efficacy, continuation rates and adverse event profiles of each injectable agent as monotherapy or in combination. The secondary outcome measurement was to discuss available guidelines that inform clinical practice for injectable agents 
520 |a RESULTS: ICIs demonstrate clinical efficacy in 54-100% of patients, early discontinuation rates of ≤ 38% and adverse events in ≤ 26%. Discontinuation rates are typically greatest within 3-6 months of commencement. Anxiety related to the initial injection occurs in approximately 65% and anxiety levels can remain high for 4 months. Approval of intracavernosal injection agents is mainly limited to alprostadil with the recent addition of aviptadil/phentolamine combination therapy in a select few geographical regions. Although combination therapies are attractive alternative options, their formulations are variable and should be standardised before widespread acceptance is achieved 
520 |a CONCLUSIONS: ICIs are associated with good clinical efficacy rates, high discontinuation rates and a moderate side-effect profile. They represent an important tool in the urological armamentarium for treating ED in patients that cannot tolerate or are refractory to oral therapies 
611 2 7 |a Journal Article  |2 gnd 
655 7 |a Erectile dysfunction (ED)  |2 gnd 
655 7 |a Intracavernosal injections  |2 gnd 
655 7 |a Treatment of ED  |2 gnd 
655 7 |a Treatment of erectile dysfunction  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 |5 DE-601 
689 1 0 |a Erectile dysfunction (ED) 
689 1 1 |a Intracavernosal injections 
689 1 2 |a Treatment of ED 
689 1 3 |a Treatment of erectile dysfunction 
689 1 |5 DE-601 
700 1 |a Omran, Ghadir J 
700 1 |a Teh, Jiasian 
700 1 |a Davis, Niall F 
700 1 |a Bolton, Damien M 
700 1 |a Lawrentschuk, Nathan 
773 0 8 |i in  |t World journal of urology  |g Vol. 37, No. 6 (2019), p. 1007-1014  |q 37:6<1007-1014  |w (DE-601)NLM074851403  |x 1433-8726 
856 4 1 |u http://dx.doi.org/10.1007/s00345-019-02727-5  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 37  |j 2019  |e 6  |c 06  |h 1007-1014